Suppr超能文献

COVID-19 与 ICU 获得性多重耐药菌定植和感染的关系:一项前瞻性多中心前后对照研究。

Relationship between COVID-19 and ICU-acquired colonization and infection related to multidrug-resistant bacteria: a prospective multicenter before-after study.

机构信息

Médecine Intensive Réanimation, Hôpital R. Salengro, CHU de Lille, Rue E. Laine, 59037, Lille Cedex, France.

Médecine Intensive Réanimation, Hospices Civils de Lyon, Hôpital Edouard Herriot, 69437, Lyon Cedex 03, France.

出版信息

Intensive Care Med. 2023 Jul;49(7):796-807. doi: 10.1007/s00134-023-07109-5. Epub 2023 Jun 16.

Abstract

PURPOSE

Patients presenting the most severe form of coronavirus disease 2019 (COVID-19) pneumonia, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have a prolonged intensive care unit (ICU) stay and are exposed to broad-spectrum antibiotics, but the impact of COVID-19 on antimicrobial resistance is unknown.

METHODS

Observational prospective before-after study in 7 ICUs in France. All consecutive patients with an ICU stay > 48 h and a confirmed SARS-CoV-2 infection were included prospectively and followed for 28 days. Patients underwent systematic screening for colonization with multidrug-resistant (MDR) bacteria upon admission and every week subsequently. COVID-19 patients were compared to a recent prospective cohort of control patients from the same ICUs. The primary objective was to investigate the association of COVID-19 with the cumulative incidence of a composite outcome including ICU-acquired colonization and/or infection related to MDR bacteria (ICU-MDR-col and ICU-MDR-inf, respectively).

RESULTS

From February 27th, 2020 to June 2nd, 2021, 367 COVID-19 patients were included, and compared to 680 controls. After adjustment for prespecified baseline confounders, the cumulative incidence of ICU-MDR-col and/or ICU-MDR-inf was not significantly different between groups (adjusted sub-hazard ratio [sHR] 1.39, 95% confidence interval [CI] 0.91-2.09). When considering both outcomes separately, COVID-19 patients had a higher incidence of ICU-MDR-inf than controls (adjusted sHR 2.50, 95% CI 1.90-3.28), but the incidence of ICU-MDR-col was not significantly different between groups (adjusted sHR 1.27, 95% CI 0.85-1.88).

CONCLUSION

COVID-19 patients had an increased incidence of ICU-MDR-inf compared to controls, but the difference was not significant when considering a composite outcome including ICU-MDR-col and/or ICU-MDR-inf.

摘要

目的

由严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引起的 2019 年冠状病毒病(COVID-19)肺炎最严重形式的患者需要在重症监护病房(ICU)长时间接受治疗,并接受广谱抗生素治疗,但 COVID-19 对抗菌药物耐药性的影响尚不清楚。

方法

这是一项在法国 7 家 ICU 进行的观察性前瞻性前后对照研究。所有 ICU 入住时间超过 48 小时且 SARS-CoV-2 感染得到确认的连续患者均前瞻性纳入,并随访 28 天。患者在入院时和随后的每周进行系统的多药耐药(MDR)细菌定植筛查。COVID-19 患者与来自同一 ICU 的近期前瞻性对照患者进行比较。主要目的是研究 COVID-19 与包括 ICU 获得性 MDR 细菌定植和/或感染(分别为 ICU-MDR-col 和 ICU-MDR-inf)在内的复合结局的累积发生率之间的关联。

结果

从 2020 年 2 月 27 日至 2021 年 6 月 2 日,共纳入 367 例 COVID-19 患者,并与 680 例对照进行比较。在调整了预先指定的基线混杂因素后,两组之间 ICU-MDR-col 和/或 ICU-MDR-inf 的累积发生率没有显著差异(调整后的亚比值 [sHR] 1.39,95%置信区间 [CI] 0.91-2.09)。当分别考虑两个结局时,COVID-19 患者的 ICU-MDR-inf 发生率高于对照组(调整后的 sHR 2.50,95%CI 1.90-3.28),但两组之间 ICU-MDR-col 的发生率没有显著差异(调整后的 sHR 1.27,95%CI 0.85-1.88)。

结论

与对照组相比,COVID-19 患者 ICU-MDR-inf 的发生率增加,但考虑到包括 ICU-MDR-col 和/或 ICU-MDR-inf 在内的复合结局时,差异无统计学意义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验